Brands like Kourtney Kardashian's Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Ozempic and similar drugs are often effective because they produce feelings of satisfaction, in line with the NBC theory of ...

Novo Nordisk's decision to stop insulin pen production poses a serious challenge to diabetes care in South Africa, where ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

What if you would like to do some drinking on Ozempic? Digging into the answers with your healthcare team is essential. "We ...

New drugs from public and private companies are ... These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion ...

The randomized study lasted just 3 months, but researchers saw “multiple cardiometabolic benefits” beyond weight loss.

In a consultation the UK's drugs watchdog has now proposed the NHS expands its use for weight loss for those who are severely ...